Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA First-Cycle ANDA Approvals Not Rising Along With Full Clearances

Executive Summary

While FDA is on pace to again break its record for full ANDA approvals in FY 2019, the first-cycle approval rate is dropping, as illustrated in our charts.

Related Content

Generic Drug Application Submission Downturn Continued In June
Generics Firms Race To Withdraw ANDAs
Generic Companies Race To Withdraw ANDAs
Rounding Up And Down: Assessing FDA FY 2019 and FY 2020 Workload Estimates
US FDA Sets Generic Approval Record, But Generic Sponsors Aren't Celebrating
US FDA May Start Missing ANDA User Fee Goals – In Order To Speed Approvals
ANDA Sponsors Need To 'Slow Down' And Focus On Quality, US FDA Generics Director Says
US FDA's Generics Program Reaches 'Steady State' Milestone
Let's Get Real – ANDA Approval Likely Takes More Than Two Years, US FDA Says
No More 'Hidden' Facilities, US FDA Tells Generic Sponsors





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts